Evidence map›Paper›PMID 39143905›Full record

ArticleJournal of applied physiology (Bethesda, Md. : 1985)2024

Coadministration of PEGylated apohemoglobin and haptoglobin can limit vascular dysfunction in the microcirculation and prevent acute inflammation.

Carlos J Munoz, Daniela Lucas, Cynthia R Muller, Jacinda Martinez, Quintin O'Boyle, Ivan S Pires, Andre F Palmer, Pedro Cabrales

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of applied physiology (Bethesda, Md. : 1985), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Carlos J MunozDepartment of Bioengineering, University of California, San Diego, California, United States.ORCID 0000-0003-4832-3661
Daniela LucasDepartment of Bioengineering, University of California, San Diego, California, United States.ORCID 0009-0005-0101-4628
Cynthia R MullerDepartment of Bioengineering, University of California, San Diego, California, United States.
Jacinda MartinezDepartment of Bioengineering, University of California, San Diego, California, United States.
Quintin O'BoyleWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0003-1499-9620
Ivan S PiresWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-4035-0027
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, United States.ORCID 0000-0002-3378-3772
Pedro CabralesDepartment of Bioengineering, University of California, San Diego, California, United States.ORCID 0000-0002-8794-2839

Funding

Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Training in Bioengineering Research and Technology Development in Cardiovascular in Cardiopulmonary Health and DiseaseT32HL160507 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karen L Christman, Andrew D. McCulloch · 2022 to 2026
$1.6M
National Institute of Health Sciences (NIHS) R01HL159862National Institute of Health Sciences (NIHS) R01HL162120NHLBI NIH HHS R01 HL159862NHLBI NIH HHS R01 HL162120NHLBI NIH HHS T32 HL160507
6 · The paper itself

Abstract

Unfortunately, during pathological conditions resulting in chronic hemolysis cell-free hemoglobin (Hb) is released into the circulation that releases free heme, resulting in several complications. One approach to prevent these toxicities is the administration of supplemental scavenger proteins, haptoglobin (Hp) and hemopexin (Hpx). The goal of this body of work is to objectively measure the levels of vascular reactivity and inflammatory profiles after an infusion of acellular hemoglobin in animals that were given a coadministration of PEGylated human apohemoglobin (PEG-apoHb), a hemopexin (Hpx)-mimetic that can scavenge free heme from hemoglobin, together with human plasma-derived Hp that can scavenge dimerized Hb. Using intravital microscopy, Golden Syrian hamsters instrumented with a dorsal window chamber were used to evaluate the in vivo effects of four experimental groups that were then challenged with a hypovolemic injection (10% of the animal's blood volume) of human Hb (hHb, 5 g/dL). The four experimental groups consisted of:

Indexed as

HaptoglobinsHemoglobinsHemopexinInflammationMesocricetusMicrocirculationPolyethylene GlycolsAnimalsCricetinaeHumansMaleHaptoglobinsHemoglobinsHemopexinPolyethylene Glycolscoadministrationhaptoglobin (Hp)hemolysishemopexin (Hpx)PEGylated human apohemoglobin (PEG-apoHb)

Identifiers

PMID39143905
PMCPMC11486475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.